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Primary pulmonary hypertension (PPH) is a potentially lethal disorder, because the elevation of the pulmonary
arterial pressure may result in right-heart failure. Histologically, the disorder is characterized by proliferation of
pulmonary-artery smooth muscle and endothelial cells, by intimal hyperplasia, and by in situ thrombus formation.
Heterozygous mutations within the bone morphogenetic protein type II receptor (BMPR-II) gene (BMPR2), of the
transforming growth factor b (TGF-b) cell–signaling superfamily, have been identified in familial and sporadic cases
of PPH. We report the molecular spectrum of BMPR2 mutations in 47 additional families with PPH and in three
patients with sporadic PPH. Among the cohort of patients, we have identified 22 novel mutations, including 4
partial deletions, distributed throughout the BMPR2 gene. The majority (58%) of mutations are predicted to lead
to a premature termination codon. We have also investigated the functional impact and genotype-phenotype re-
lationships, to elucidate the mechanisms contributing to pathogenesis of this important vascular disease. In vitro
expression analysis demonstrated loss of BMPR-II function for a number of the identified mutations. These data
support the suggestion that haploinsufficiency represents the common molecular mechanism in PPH. Marked
variability of the age at onset of disease was observed both within and between families. Taken together, these
studies illustrate the considerable heterogeneity of BMPR2 mutations that cause PPH, and they strongly suggest
that additional factors, genetic and/or environmental, may be required for the development of the clinical phenotype.
Introduction
Familial primary pulmonary hypertension (PPH [MIM
178600]) is an autosomal dominant disorder character-
ized by obliteration of the pulmonary arteries, which
leads to sustained elevation of pulmonary vascular re-
sistance (mean pressure 125 mmHg at rest, 130 mmHg
during exercise) and progressive right-heart failure
(Rubin 1997). The disease gene acts with markedly re-
duced penetrance, and the majority of patients (190%)
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have no known family history of the disease. In both
familial and sporadic PPH, the disease is twice as com-
mon in females as in males, and symptoms typically
develop during the 3d decade of life, although the disease
may occur at any age (Rich et al. 1987; Gaine and Rubin
1998). A number of potential environmental triggers for
the development of the disease have been recognized in
recent years, including prolonged use of appetite-sup-
pressant drugs (e.g., dexfenfluramine and fenfluramine),
infection with HIV, and consumption of adulterated
rapeseed oil (Gomez-Sanchez et al. 1991; Abenhaim et
al. 1996; Mesa et al. 1998; Thomson and Trembath, in
press). Treatment strategies have relied on the use of oral
anticoagulants and vasodilators. More recently, the use
of prostacyclin analogues has improved life expectancy,
with heart and/or lung transplantation as a further treat-
ment option (Rich et al. 1992; McLaughlin et al. 1998).
Pulmonary hypertension may occur as a secondary
phenomenon in patients with various diseases, including
recurrent thromboembolism, chronic hypoxic lung dis-
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ease, and left-heart disease. However, until recently the
etiology of PPH has been poorly understood. Linkage
analysis in affected families mapped the familial PPH
locus to chromosome 2q33, with no evidence for locus
heterogeneity (Morse et al. 1997; Nichols et al. 1997;
Deng et al. 2000a; Machado et al. 2000). Using a po-
sitional candidate-gene strategy, we and others recently
have demonstrated that mutations in the bone mor-
phogenetic protein type II receptor (BMPR-II) gene
(BMPR2) cause familial PPH (Deng et al. 2000b; The
International PPH Consortium et al. 2000). We have
also demonstrated that germline mutations of BMPR2
are found in26% of sporadic cases of PPH (Thomson
et al. 2000).
BMPR2 encodes a type II receptor member (BMPR-
II) of the transforming growth factor b (TGF-b) super-
family of cell-signaling molecules (Liu et al. 1995). After
ligand binding, type II receptors, which have serine/thre-
onine kinase activity, form heteromeric complexes with
membrane-bound type I receptors, initiating phosphor-
ylation of the type I receptor and downstream intra-
cellular Smads (Massague and Chen 2000). This diverse
pathway appears to be critical in both cell differentia-
tion and cell growth, with specificity mediated through
transcriptional regulation. Of considerable interest, de-
fects of two additional components of the TGF-b path-
way (endoglin (ENG) and the activin receptor–like ki-
nase-1 gene [ACVRLK1]) have been demonstrated in
some families with another vascular disorder, hereditary
hemorrhagic telangiectasia (MIM 187300 and MIM
600376) (McAllister et al. 1994; Johnson et al. 1996;
Marchuk 1998).
Our initial findings suggest that, although heterozy-
gous germline mutations are required for inheritance of
PPH, they may not be sufficient for the development of
the disease phenotype. Furthermore, our findings raise
important questions regarding the molecular mecha-
nisms that lead to the pathogenesis of the vascular le-
sions seen in PPH. To obtain data to enhance the un-
derstanding of the functional significance of BMPR2
mutations in PPH, we have investigated both an addi-
tional 47 unrelated families with PPH and three patients
with sporadic PPH. We report 23 novel mutations of
the BMPR2 gene that, taken together with in vitro func-
tional analyses, support a model of haploinsufficiency
as the molecular mechanism for the dominant inheri-
tance of this important vascular disorder.
Families and Methods
Families
Probands with familial PPH were identified in 47 un-
related families by specialist physicians at major organ-
transplant centers. Individuals were defined as affected
if cardiac catheterization revealed normal pulmonary-
artery wedge pressure and pulmonary hypertension
(mean pulmonary artery pressure 125 mmHg) or if au-
topsy results showed plexogenic pulmonary arteriopathy
(Gaine and Rubin 1998). We excluded patients with sec-
ondary causes of pulmonary hypertension, including
other diseases of the heart and lung, pulmonary em-
bolism, connective-tissue diseases, and the use of ap-
petite-suppressant drugs (Thomson and Trembath, in
press). All families are of western European origin. For
assessment of genotype/phenotype correlation, age at
onset was defined as the first age at which relevant symp-
toms or clinical signs were recorded. To document the
number of relatives affected with PPH, a structured in-
terview was performed, including a detailed family his-
tory (by J.R.T., L.W., or the local PPH specialist team).
Affected status was confirmed through autopsy reports,
histological review by transplant center pathologists,
and assessment of medical records. Unaffected status
was assigned to related family members with either no
symptoms or signs of disease and/or after indirect mea-
surement of pulmonary artery pressures by Doppler
echocardiography. All available data were assessed by a
physician specializing in PPH (J.E.L., J.N., N.G., M.H.,
K.M., P.C., G.M., and L.T.), according to World Health
Organization criteria (Thomson and Trembath, in
press). DNA was extracted, by standard methods, from
whole blood, lymphoblastoid cell lines, or pathological
tissue specimens. All samples were collected after par-
ticipants gave informed consent, and the study was ap-
proved by the Leicestershire Health Authority Ethics
Committee, the Huntingdon Local Research Ethics
Committee, the Royal Brompton and Harefield National
Health Service Trust Ethics Committee, the South Man-
chester Local Research Ethics Committee, the West Glas-
gow Hospitals University National Health Service Trust,
and the institutional review boards of the individual
institutions.
Mutation Analysis of the BMPR2 Gene in Families
with PPH
The entire protein-coding region and intron/exon
boundaries of the BMPR2 gene were amplified by PCR
using DNA samples from affected individuals and
primer pairs specific for all 13 exons, as described else-
where (The International PPH Consortium et al. 2000).
PCR products were separated by electrophoresis through
4% agarose (3% Nusieve [FMC Bioproducts] and 1%
agarose [Gibco BRL]), to ensure the presence of suffi-
cient quantities for sequence analysis, and were purified
using the QIAquick 96 PCR purification kit (QIAGEN).
PCR products were sequenced using the same primers
as for the PCR reactions, on either an ABI 377 sequencer
or an ABI 3700 DNA analyzer, with the Applied Bio-
systems DyeDeoxy or BigDye terminator kit. Using PCR
amplification of the relevant exon, followed by either
Table 1
BMPR2 Mutations Identified in 23 Families with PPH and in Three Patients with Sporadic PPH
Familya
Mutation
Location Nucleotide Changeb Amino Acid Changec
Segregation
No. Affected
Individuals/
Generations
Age(s) at Onsetd
(years)
Ages of Asymptomatic
Obligate Gene Carriers
(years)
UKSp14 Exons 1–6 51–814 del T17fs(7 amino acids) Direct sequencing 1/1 26 …
UKSp15 Exon 1 Undetermined 5′ deletion … Dosage 1/1 31 …
UK01 Exon 1 Undetermined 5′ deletion … Dosage 8/3 1–42 57, 72 (living); 66 (deceasede)
US70 Exon 1 44delC P15fs(30 amino acids) NcoI 2/2 36–38 …
US42 Exon 2 156–157delTC S52fs(0 amino acids) Direct sequencing 3/1 32–39 …
UK09 Exon 3 367TrC C123R MseI 2/1 9–26 …
NOR01 Exon 3 367TrA C123S MseI 5/2 NR …
US37 Exon 4 439CrT R147X DdeI 3/2 10–39 …
UK21 Exon 4 504insT L168fs(11 amino acids) Direct sequencing 2/2 13–19 …
ITA01 Exon 6 631CrT R211X Taq1 2/1 17–18 …
US44 Exon 6 689–690delAA K230fs(23 amino acids) Direct sequencing 3/2 4–46 …
FRA04 Exon 6 727GrT E243X Direct sequencing 2/2 40 …
UK04 intron 7 IVS7 9583 delT Inactivates exon 7 donor site Direct sequencing 8/4 14–60 39, 45, 52 (living); 86 (deceasedf)
US50 Exon 8 994CrT R332X TaqI 2/2 28–32 …
US13 Exon 8 994CrT R332X TaqI 8/3 13–42 45, 71
US94 Exon 8 1076delC T359fs(14 amino acids) BsrI, XcmI 2/2 39–42 …
US80 intron 8 IVS8 1129–3CrG Inactivates exon 9 acceptor site MnlI 6/3 24–53 …
US89 Exon 9 1191/1192delTG C397fs(0 amino acids) HinfI 2/1 26 …
GER01 Exon 9 1258TrC C420R MaeI 4/2 9–40 …
GRE01 Exon 11 1535ArC K512T Direct sequencing 2/2 19–50 …
SWE01 Exon 12 1750CrT R584X Direct sequencing 2/2 34 …
UK22 Exon 12 2292insA N764fs(47 amino acids) Direct sequencing 3/2 30–57 …
US79 Exon 12 2408insTG T803fs(3 amino acids) HphI 2/1 51–52 …
UK11 Exon 12 2579–2580delT I860fs(10 amino acids) AseI 3/2 2–22 …
US91 Exon 12 2695CrT R899X HaeIII 2/1 27–32 …
UKSp16 Exon 12 Undetermined 3′ deletion … Dosage 1/1 22 …
a FRA p France; GER p Germany; GRE p Greece; ITA p Italy; NOR p Norway; Sp p patient with sporadic PPH; SWE p Sweden; UK p United Kingdom; US p United
States.
b Nucleotide numbers are according to published cDNA, with the A of the ATG designated as 1.
c Frameshifts are denoted with the amino acid, position, and number of amino acids until the next stop codon.
d NR p information not released.
e Because of breast cancer.
f Because of cerebrovascular accident.
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Figure 1 BMPR2 cDNA structure and location of all reported PPH mutations. Exons are numbered 1–13, and their boundaries are
indicated by the solid black lines segmenting the cDNA schematic. Extracellular/ligand binding, transmembrane, kinase, and cytoplasmic tail
domains of BMPR-II are defined as indicated. Mutations shown above the BMPR2 cDNA are newly reported in this study, whereas those
shown below have been reported elsewhere (Deng et al. 2000b;The International PPH Consortium et al. 2000; Thomson et al. 2000). Underlined
mutations have been reported in patients with sporadic PPH (Thomson et al. 2000); asterisks (*) indicate mutations that were independently
reported (Deng et al. 2000b). Frameshift mutations (fs) are denoted by the one-letter amino acid abbreviation and amino acid–position number
at which the mutation occurs, followed by the number of extra amino acids before the next stop codon—for example, L168fs (11).
mutation-specific RFLP analysis or direct sequencing, we
confirmed segregation of the mutations within families
and excluded the presence of the mutations in a panel
of 150 chromosomes from normal individuals.
Haplotype Analysis to Determine Origins of Recurrent
Mutations
Genotyping of polymorphic markers around the
BMPR2 gene was performed as described elsewhere for
individuals from different families found to carry the
same mutation (Machado et al. 2000). Alternatively, ge-
notype analysis for a BMPR2 intron 1 tetranucleotide
repeat, using primers 5′-TGGAAGGTTAGATGCAAA-
TGG-3′ (forward) and 5′-GTGAAGGTTGCAGTGAG-
CAG-3′ (reverse), was performed by PCR amplification.
RNA Extraction and Reverse Transcriptase (RT) PCR
Total RNA was extracted from lymphoblasts or whole
lung tissue, by use of the RNAzol B kit (AMS Biotech-
nology), and 2.5 mg of total RNA was reverse transcribed
using 25 ng of primer R1 (5′-CACCCCGCCCGGTAA-
ACATC-3′). After the RNA was heated for 10 min at
65C, 1# RT buffer, 10 mM DTT, 500 mM of dNTP,
40 U of RNase inhibitor, and 200 U Moloney murine
leukemia virus RT (Gibco BRL) were added, and the
mix was incubated at 42C for 1 h. The entire coding
sequence was amplified in two overlapping fragments of
2,075 bp (exons 1–12) and 1,183 bp (exons 12 and 13).
A primary PCR was performed for each fragment, as
described above for genomic DNA amplification. A
heminested PCR was then performed by addition of 1
ml of the primary PCR product to a secondary PCR mix,
as described above. Secondary products were then sep-
arated by electrophoresis on a 1.5% agarose gel.
Fluorescent-Dosage PCR
A quantitative fluorescent multiplex PCR reaction was
performed, as described elsewhere (Morgan et al. 1999),
to amplify fragments of exons 1 and 12 of the BMPR2
gene, along with exon 4 of the SURF6 gene (primers 5′-
AGTGGGTGCCTCTTTCC-3′ and 5′-TGAAGCTAA-
CAAGGGGCAAC-3′), which served as an internal con-
trol. All forward primers were labeled with a fluorescent
dye (Applied Biosystems). To keep the reactions within
96 Am. J. Hum. Genet. 68:92–102, 2001
the exponential phase, only 19 cycles of PCR were per-
formed in a 25-ml reaction with 125 ng of genomic DNA
and 0.25 mM each of forward and reverse primer, as
described above. A 1-ml aliquot of PCR product was
added to 1.5 ml of formamide loading buffer (95% for-
mamide in 1# Tris-borate EDTA and 5 mg dextran blue/
ml) and 0.5 ml of internal lane size standard (Genescan-
500 Rox; Applied Biosystems). Samples were denatured
for 5 min at 95C and were separated by electrophoresis
on a 6% denaturing polyacrylamide gel for 3 h by an
ABI 377 fluorescent DNA sequencer. Data were analyzed
by GENESCAN and GENOTYPER software to obtain
electropherograms for each sample. The copy numbers
of BMPR2 exons 1 and 12 in the patient samples were
determined by calculation of a dosage quotient, using
the area below the peaks for the amplification products
relative to those of the control sample. The dosage quo-
tient for BMPR2 exon 1 is calculated as follows: [patient
sample BMPR2 exon 1/patient sample SURF6 exon 4]/
[control BMPR2 exon 1/control SURF6 exon 4].
In Vitro Expression of Recombinant BMPR-II
Plasmid constructs.—Plasmids were constructed by di-
gesting the BMPR2 cDNA from CL4-1 (kindly provided
by H. Moses) with XhoI and SalI. This 3.3-kb fragment
was ligated into XhoI/SalI-digested pCI-neo (Promega).
Clones were confirmed by restriction digest and DNA
sequencing. To generate the mutations used for the in
vitro expression studies the initial construct was sub-
jected to site-directed mutagenesis, according to the Stra-
tagene QuickChange (200518) protocol. Independent
transformants were screened by amplification of the ap-
propriate fragment from recovered plasmid and by re-
striction digestion to confirm the altered site. Results of
this assay were confirmed by restriction endonuclease
digestion of the intact isolated plasmid.
Functional studies.—The expression system used the
normal mouse mammary-gland epithelium (NMuMG)
cell line that is constitutively competent for TGF-b sig-
naling (Piek et al. 1999). NMuMG cells (American Type
Culture Collection CRL-1636) were grown in Dulbec-
co’s minimal essential medium (DMEM), supplemented
with 4.5 g glucose/liter, 0.584 g L-glutamine/liter, 100
U/100 mg penicillin-streptomycin/ml, and 10% fetal bo-
vine serum. Cells were plated at ∼3# 105 cells per well,
in six-well Falcon plates (Falcon). After 24 h, the media
were removed, and the wells were washed once with
Hanks’ balanced salt solution (LifeTechnologies). Trans-
fection was accomplished by addition, to each well, of
0.5 ml of OptiMEM (LifeTechnologies) containing 2 mg
of plasmid DNA complexed with Lipofectamine
(LifeTechnologies) as a transfection reagent. The trans-
fection reagent was prepared by addition of 14 mg of
plasmid DNA to 3.5 ml of OptiMEM in polystyrene
tubes (Falcon), followed by addition of 70 ml of lipo-
fectamine. The mixture was agitated lightly, was incu-
bated at 37C for 30 min, and then was applied to the
washed wells. The plates were incubated at 37C, under
5% CO2 for 8 h, and then 0.5 ml of supplemented
DMEM was added to the wells, and the incubation con-
tinued for 16 h.
The transfection experiments consisted of cotransfec-
tion of three different plasmids. The reporter plasmid
was pSBE, described by Jonk et al. (1998), which uses
a Smad-binding element (SBE) and luciferase reporter.
The plasmid for initiating the signal was either a
BMPR2-containing plasmid, as described above, or a
constitutively active activin type 1 receptor as a control
for maximum signal amplitude. Finally, a plasmid ex-
pressing the heat-stable alkaline phosphatase (AP) gene
under the control of the cytomegalovirus (CMV) pro-
moter was added as a control for transfection efficiency.
The ratio of the reporter:signal initiator:transfection
control plasmids was 2:1:1. A CMV-driven chloram-
phenicol acetyl transferase reporter was added to adjust
the plasmid quantity to 2 mg, where necessary.
The DNA liposome–containing medium was removed
at the conclusion of the 16-h incubation and was re-
placed by DMEM, as described above, except that it
contained 0.1% FBS and no antibiotic. After 8–16 h,
50 ng BMP4/ml was added to one-half of the wells.
Incubation with ligand or a similar amount of diluent
continued for 16–24 h, at which time the media were
removed and assayed for heat-stable AP and the cells
were lysed according to the manufacturer’s instruction
for the luciferase assay (Promega). The luciferase deter-
mination, measured as relative light units (RLU), was
done according to the manufacturer’s protocol and was
normalized to the AP activity in the retained media.
Results
Mutation Analysis of the BMPR2 Gene
Results of the BMPR2 mutation analysis in families
with PPH are summarized in table 1 and figure 1. A total
of 26 mutations were identified, accounting for 23 of
the 47 families with PPH and for the three patients with
sporadic PPH. All these mutations were shown to seg-
regate with the disease in families with additional mem-
bers available, and none were detected in a panel of 150
chromosomes from normal individuals. Figure 2 dem-
onstrates familial segregation for two of the newly iden-
tified mutations.
Fifteen of the 26 mutations are either frameshift
( ) or nonsense ( ) mutations that would benp 9 np 6
predicted to result in a truncated BMPR-II molecule. The
nine frameshift mutations are dispersed throughout the
gene, with the mutation closest to the 5′ end occurring
in exon 1 and with the frameshift closest to the 3′ end
found in exon 12. The exon 1 frameshift mutation would
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Figure 2 Cosegregation and sequence analysis of BMPR2 mutations in two kindreds with PPH. Black symbols denote affected individuals,
and white symbols denote unaffected individuals. Nucleotides are numbered according to the cDNA sequence, with the adenosine of the initiation
codon assigned 1. Family US13 (top) carries a CrT substitution at nucleotide 994, as shown in the chromatogram (top, right). Segregation
of the mutations was tracked through the family by TaqI digestion of exon 8 PCR products shown on the agarose gel below the pedigree. Gene
carriers are detected by presence of a 288-bp band due to loss of a TaqI site. Gel lanes correspond to the individuals numbered in the pedigree.
Family Nor01 (bottom) carries a TrA substitution at nucleotide 367, as shown in the chromatogram (bottom, right). MseI digestion of exon
3 PCR products was used to track inheritance of the mutations through the family, as shown on the agarose gel below the pedigree. The
mutation is evidenced by gain of an MseI site, resulting in the generation of 227- and 87-bp fragments. Individuals are identified by numbers
corresponding to those on gels.
predict a protein containing only the 15 N-terminal
amino acids of BMPR-II, with an additional 30 amino
acids until the next stop codon.
Six nonsense mutations, accounting for seven of the
families, are found in exons 4, 6, 8, and 12. The same
exon 8 R332X mutation was detected in two unrelated
families with two different nonsense mutations (R584X
and R899X) in exon 12. An exon 6 nonsense mutation
(E243X) results from a GrT substitution at nucleotide
727, changing a GAA glutamic acid codon to a TAA
stop codon.
Four missense mutations are found in exons 3, 9, and
11. Two different exon 3 missense mutations were iden-
tified at codon 123. A TrC substitution at nucleotide
367 results in the substitution of cysteine 123 by arginine
in family UK09, whereas a TrA change at the same
nucleotide results in a substitution of cysteine 123 by
serine in family Nor01. Shown in table 2 are six nucle-
otide changes believed to represent polymorphisms, be-
cause they were also observed in individuals not at risk
for the disease. One of the polymorphisms, a silent mu-
tation at codon 937 in exon 12, appears to be common,
since it was detected in 15 unrelated families. The re-
maining five polymorphisms, each of which was found
in three or fewer families, appear to be less common.
Identification of Deletion Variants by Fluorescent-Gene
Dosage
When fluorescent gene–dosage PCR was used, one af-
fected individual from family UK01 was observed to
have a dosage quotient of 0.46 for BMPR2 exon 1 PCR
products, relative to an internal control PCR from exon
4 of the SURF6 gene (fig. 3). Normal levels of BMPR2
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Table 2
BMPR2 Polymorphisms
Location of
Polymorphism
Nucleotide
Changea
Amino Acid
Change
No. of
Families
Exon 6 672GrT E672D 3
Exon 8 1107ArG E369E 1
Exon 12 2811GrA R937R 15
Intron 3 IVS3 420-43 delT … 2
Intron 4 IVS4 52964 CrT … 1
a Nucleotide numbers are according to published cDNA, with
the A of the ATG designated as 1.
Figure 3 Detection of heterozygous deletions of the BMPR2
gene. A, Fluorescent-dosage PCR of an affected individual in family
UK01. The patient demonstrates a reduction of 50% in peak intensity
for exon 1 of the BMPR2 gene, compared with both exon 4 of the
SURF6 gene and exon 12 of the BMPR2 gene. This indicates a het-
erozygous deletion encompassing at least exon 1 of the BMPR2 gene.
Also shown is an electropherogram from a normal control subject, in
whom peaks for all three PCR products are approximately equal. B,
Sequence analysis of BMPR2 lung mRNA RT-PCR products of UK
sporadic 14 subject. An RNA product with nucleotide 50 contiguous
to nucleotide 815 was detected by sequence analysis, as seen in the
chromatogram. The normal-sized RT-PCR product was also identified,
indicating that this patient is heterozygous for a deletion of nucleotides
51–814.
exon 12 PCR products were detected in this patient,
indicating that this patient with PPH is heterozygous for
at least a partial deletion of the BMPR2 gene, the extent
of which remains to be determined. This result was con-
firmed in one obligate gene carrier and in four individ-
uals bearing the disease haplotype in family UK01. Two
additional partial gene deletions were detected by this
technique in two patients with sporadic PPH. A dosage
quotient of 0.41 for exon 1 was observed for patient
UKSp15, indicating a heterozygous partial deletion in
the 5′ portion of the gene. Similarly, UKSp16 yielded an
exon 12 dosage quotient of 0.46, suggesting a hetero-
zygous deletion in the 3′ portion of BMPR2. The extent
of each deletion remains to be characterized.
Characterization of Deletion and Splice-Site Mutations
by RT-PCR
RT-PCR using mRNA isolated from whole-lung tissue
of a patient (UKSp14) with sporadic PPH yielded a PCR
product deleted for nucleotides 51–814 of the BMPR2
cDNA, encompassing the last 26 nucleotides of exon 1,
all of exons 2–5, and two-thirds of exon 6 (fig 3). The
normal PCR product was also present, indicating het-
erozygosity for this event. This mRNA would be pre-
dicted to encode a protein consisting of the N-terminal
16 amino acids of BMPR-II plus 7 additional amino
acids before the next stop codon.
DNA sequence analysis in two families identified mu-
tations in the consensus splice sites of two different in-
trons, indicating potential splicing variants (fig. 2). The
first of these is a heterozygous one-base deletion in the
third nucleotide of intron 7 in family UK04 (table 1).
RT-PCR products from lymphocyte mRNA from a pa-
tient yielded a heterozygous template consisting of exon
6 spliced either to exon 7 or directly to exon 8, with
exon 7 skipped (fig. 4). This abnormally spliced mRNA
would predict a protein consisting of the first 284 amino
acids of BMPR-II, with 11 additional amino acids until
the next stop codon. A CrG substitution in intron 8,
three nucleotides 5′ of exon 9, in family US80 suggests
an additional splice variant. The lack of BMPR2 mRNA
from this patient prevents confirmation of this change
as a splicing mutation.
In Vitro Expression Analysis of BMPR2 Kinase Domain
Mutation
Using site-directed mutagenesis, we generated the pre-
viously reported kinase domain missense mutation
D485G (The International PPH Consortium et al. 2000).
Either full-length wild-type BMPR2 or full-length
D485G recombinant BMPR2 was cotransfected with an
SBE luciferase-reporter plasmid (pBSE) in NMuMG cells
in the presence of the ligand BMP4. As seen in figure 5,
cotransfection with the wild-typeBMPR2 yielded a mea-
surement of 4.3 # 106 RLU, whereas cotransfection
with D485G BMPR2 resulted in the production of only
1.7# 106 RLU. Results obtained with the recombinant
molecule are similar to those obtained with transfection
of only pBSE in the absence of any exogenous type II
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Figure 4 Sequence analysis of RT-PCR products for a hetero-
zygous BMPR2 intron 7 splice-site mutant. The splice-site mutation
leads to skipping of exon 7 in the mutant. Nucleotides are listed above
the sequencing peaks and indicate the end of exon 6, joined with the
beginning of exon 7 or exon 8 in the normal or mutant, respectively.
The arrow indicates the splice junction between exon 6 and either
exon 7 or 8. Exon 7 sequence can be seen as the higher peaks in the
right half of the chromatogram, with exon 8 represented by the lower
peaks.
Figure 5 In vitro expression analysis of wild-type and mutant
BMPR2 in NMuMG cells. The control transfection using only the SBE
reporter plasmid in the presence () or absence () of the ligand BMP4
measures activation of endogenous type II receptor function. Cotrans-
fection of the SBE reporter with either wild-type or mutant BMPR2
constructs determines functional activity of the exogenous BMPR-II.
Cotransfection of wild-type BMPR2 and the SBE reporter yielded a
twofold increase in reporter activity. In contrast, cotransfection of
mutant BMPR2 yielded functional activity equivalent to that of the
endogenous receptor, indicating loss of function for both mutants.
receptor (2.0 # 106 RLU), a result that is consistent
with loss of function of the BMPR-II molecule contain-
ing the D485G substitution. Similar results were ob-
tained on expression of a mutant plasmid containing a
frameshift mutation in exon 12 (fig. 5).
Haplotype Analysis for Recurrent BMPR2 Mutations
Three of the mutations in the present study have been
reported elsewhere (The International PPH Consortium
et al. 2000; Thomson et al. 2000). Affected individuals
from two unrelated families, US13 and US50, were
shown to carry the R332X nonsense mutation previ-
ously seen in a patient with sporadic PPH (Thomson et
al. 2000). Another family (UK11) was shown to carry
the previously reported I860fs(10) familial mutation,
and the R899X nonsense mutation, previously detected
in both familial and sporadic PPH, was identified in 1
(US91) of the 47 families (The International PPH Con-
sortium et al. 2000; Thomson et al. 2000). None of the
individuals carrying the same mutations shared the same
disease haplotype, indicating independent origins for all
of the recurrent mutations.
Genotype and Disease Onset
The observed overall range for the age at onset of
symptoms of PPH was 1–60 years (table 1). Marked
variation in the age at onset was noted both within fam-
ilies and between families that had the same BMPR2
mutation. For example, in family UK04, the age at onset
for the eight affected individuals was 14–60 years. In
families US13 and US50, both carrying the R332X mu-
tation, the mean age at onset was 28 and 30 years, re-
spectively, with a range of 13–42 years in the eight af-
fected individuals in US13, whereas the lowest age at
onset in US50 was 28 years. These data show no cor-
relation between type of BMPR2 mutation and pene-
trance of PPH, either in terms of number of affected
individuals within a family or age at onset of disease.
Furthermore, the range and nature of the presenting
symptoms were similar between families with and with-
out identified BMPR2 mutations.
Discussion
In this study, we have identified heterozygous mutations
of the BMPR2 gene in 23 of 47 studied families as well
as in three individuals with sporadic PPH. Twenty-two
of the mutations are novel, and elsewhere we have re-
ported four of the mutations in other patients with fa-
milial or sporadic PPH (The International PPH Con-
sortium et al. 2000; Thomson et al. 2000). These data
represent the first report of splice mutations as well as
the first evidence of partial deletions of the BMPR2 gene
in patients with PPH. To date, we have identified 28
novel familial PPH mutations, accounting for 32 of 55
families analyzed. We have also recently identified an
additional 11 mutations in 13 of 50 individuals with
sporadic PPH (Thomson et al. 2000). When a recent
report of 7 additional mutations in 19 families (Deng et
al. 2000b) is included, a total of 46 unique BMPR2
mutations have now been identified in patients with PPH
(fig. 1). The mutations are widely dispersed throughout
the gene and are found in all exons except 5, 10, and
13.
The first evidence that large deletions in the BMPR2
gene contribute to the development of PPH was de-
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tected, in the present study, in one patient with familial
PPH and in three patients with sporadic PPH. In one
of the patients with sporadic PPH deletions, the RT-
PCR product encompassed the last 26 nucleotides of
exon 1, all of exons 2–5, and two-thirds of exon 6.
Interestingly, the sequence ATGGAC is found on the 5′
side of the deletion breakpoints in both exon 1 and exon
6, suggesting homologous recombination as the mech-
anism producing the deletion. The identified frameshift
mutations are predicted to result from replication slip-
page, because all eight occur in regions of small mono-
or dinucleotide repeats. Independent recurrence of the
I860fs(10) frameshift mutation, resulting from a sin-
gle thymine deletion (ATTAATTrATTAAT) at either
nucleotide 2579 or nucleotide 2580 may be a conse-
quence of the sequence surrounding the deleted nucle-
otide. Not surprisingly, five of the six nonsense muta-
tions occur at CpG dinucleotides, changing a CGA
arginine codon to a TGA stop codon.
Using direct sequence analysis, we and others have
detected mutations in 40 (55%) of 73 families with PPH
(Deng et al. 2000b; The International PPH Consortium
et al. 2000). There are a number of possible explana-
tions for the 45% of families with PPH in which
BMPR2 gene mutations have not been identified. First,
the direct-sequencing methods employed in the study
may not detect all heterozygous mutations. In addition,
mutations in portions of the BMPR2 gene that were not
sequenced, such as upstream regulatory regions, 3′ UTR,
or intronic sequences, could account for PPH in these
patients, although mutations of this type are generally
infrequent in other genetic disorders. Alternatively, a
hotspot for recurrent mutation, similar to the one that
results in the common FVIII gene inversion in hemo-
philia A, could account for this observation (Lakich et
al. 1993). The extent to which gene rearrangements at
the BMPR2 locus contribute to the development of PPH
is still unknown. Finally, the possibility of genetic het-
erogeneity must be considered. Of the 23 families in
which mutations have not been detected, 13 demon-
strate either direct evidence for linkage to or allele shar-
ing at the BMPR2 locus. Although we cannot exclude
the possibility that one or more additional genes may
contribute to PPH pathogenesis,72% of families stud-
ied either have an identified BMPR2 mutation or show
evidence of linkage to the BMPR2 locus.
Through pedigree analysis of kindreds with PPH, in-
cluding several families included in the present study, it
has previously been shown that PPH is a disorder dem-
onstrating genetic anticipation (Loyd et al. 1995). Ex-
amination of the BMPR2 coding sequence fails to reveal
any triplet-repeat sequences, and PCR analysis of a
GCC repeat ∼1 kb 5′ of the initiation codon failed to
demonstrate expansion in a cohort of patients with
PPH. Thus, molecular evidence for genetic anticipation
has yet to be detected in any of the families in the present
study that demonstrate anticipation. Although expan-
sion of an undetected intronic triplet repeat in the
BMPR2 gene may account for this anticipation, it is
also possible that a novel mechanism of anticipation
occurs in families with PPH.
Assessment of the functional impact of the hetero-
geneous mutations in the BMPR2 gene is likely to pro-
vide insight into the molecular mechanisms associated
with the initiation and progression of the vascular path-
ological lesions characteristic of PPH. The majority of
nonsense and frameshift mutations, of which the mu-
tation closest to the 5′ end occurs in exon 1, lead to
premature truncation of the BMPR2 transcript. These
mutations predict nonsense-mediated mRNA decay and
absence of the production of the mutated BMPR-II poly-
peptide (Maquat 1995).
The 10 different missense mutations identified in this
and other studies, each altering highly conserved amino
acids, require further investigation of functional impact.
As evidence of the pathogenicity of these mutations,
none were detected among a panel of 150 normal chro-
mosomes. Five missense mutations have been identified
in the region coding for the extracellular/ligand-binding
domain, four in the kinase domain–encoding region,
and one immediately distal to the kinase domain–
encoding region (fig. 1). Each of the 10 missense mu-
tations introduces a nonconservative change that alters
the charge, polarity, hydrophobicity, and/or size of the
substituted amino acid residue. The five missense mu-
tations in the ligand-binding domain involve 4 of the
10 highly conserved cysteine residues. If expressed and
transported to the cell membrane, such mutant BMPR-
II polypeptides are predicted to alter the three-dimen-
sional structure of the ligand-binding domain. Such al-
terations may affect either ligand binding, type
I–receptor binding, or propagation of signal across the
membrane to the kinase domain. In vitro expression of
recombinant BMPR-II containing either the D485G mu-
tation or the I860fs(10) frameshift mutation, pre-
dicted to encode a protein containing 83% of the nor-
mal BMPR-II, demonstrated complete loss of function.
Taken together, these data strongly support the hy-
pothesis that the predominant molecular mechanism in
the dominant inheritance of PPH is one of haploinsuf-
ficiency. This suggests that the target cell(s) within the
pulmonary arterial wall are sensitive to BMPR2 gene
dosage and that the TGF-b pathway, mediated through
BMPR-II, is critical for maintenance and/or normal re-
sponse to injury of the pulmonary vasculature. How-
ever, the age at onset of disease is variable, both within
families and between subjects carrying identical but re-
current mutations (table 1). These findings, together
with the previously reported large number of individuals
in whom BMPR2 lacked penetrance (Deng et al. 2000b;
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The International PPH Consortium et al. 2000), point
to the possibility that additional factors, either envi-
ronmental or genetic, are required for the pathogenesis
of the disease. The marked sex bias (female:male ratio
2:1) for presentation of the disease suggests a role for
either a hormonal factor or an X-linked locus in disease
predisposition (Loyd et al. 1995).
The identification of germline mutations of the
BMPR2 gene as the inherited basis of PPH has impor-
tant implications for assessment and management of
patients with this dramatic vascular disease. However,
the detailed molecular mechanisms associated with
the pathogenesis of the disorder will require further
analysis, including identification of target genes whose
transcription is regulated by BMPR-II–mediated cell sig-
naling. The demonstration that gene dosage and recep-
tor activity are critical will aid the development of func-
tional experiments designed to delineate the detailed
molecular pathology of PPH.
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